Regeneron Pharmaceuticals Inc (REGN) - News Archive

Pioneering Advancements in Immunotherapy: Libtayo and Dupixent Set New Benchmarks in Cancer and Chronic Illness TreatmentsIn a significant stride for modern oncology and immunological treatments, the European Union has...

Regeneron Advances Therapeutic Frontier at ASH: Novel Data in Multiple Myeloma, Lymphoma, and Paroxysmal Nocturnal Hemoglobinuria Unveiled Regeneron Pharmaceuticals recently showcased significant progress in its hematol...

: The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions recommending approval for Libtayo (cemiplimab) in the adjuvant treatment of patients with cutaneous sq...

Libtayo (cemiplimab-rwlc) Receives FDA Approval as the First Immunotherapy for High-Risk Cutaneous Squamous Cell Carcinoma: Pioneering Treatment for Patients After Surgery and Radiation In a significant advancement in c...

Dupixent (Dupilumab) Shows Promise in Treating Chronic Spontaneous Urticaria: A New Chapter with Positive CHMP Opinion Chronic Spontaneous Urticaria (CSU) remains a perplexing and challenging condition affecting adults...

Promising Advances in Relapsed/Refractory Multiple Myeloma Treatment: Linvoseltamab Combined with Carfilzomib or Bortezomib Shows Encouraging ResultsIn a significant development for multiple myeloma patients, early resu...

Amidst heightened market volatility and fluctuating sector performances, the financial landscape on April 29, 2025, was a tale of contrasting fortunes. The trading day was marked by a significant sel...

Regeneron Pharmaceuticals, Inc. has recently announced a significant investment aimed at bolstering its manufacturing capacities for its leading biologic medicines through a new agreement with FUJIFILM Diosynth Biotechn...

EYLEA HD (Aflibercept) Gains FDA Priority Review, Could Redefine Macular Edema TreatmentRegeneron Pharmaceuticals Inc. a prominent entity in the pharmaceutical sector, has achieved a significant milestone with the U.S....

Investors on Alert: Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. In the ever-dynamic landscape of the pharmaceutical industry, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is currently navigating a legal stor...

Advances in Oncology: Linvoseltamab, EYLEA HD, and Odronextamab Signal New Era in Treatments for Refractory Conditions In an era marked by rapid advancements in pharmaceutical innovations, targeted treatments for refrac...

Regeneron Pharmaceuticals: Navigating Legal Challenges Amid Impressive Revenue Growth In the intricate landscape of the pharmaceutical industry, Regeneron Pharmaceuticals, Inc. has emerged as a notable player, despite f...

: In this examination of the securities class action involving Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), we delve into the critical aspects and potential ramifications for investors. The recent notification by the...

In a world where innovation and scientific exploration intertwine to forge advancements in technology and healthcare, the Regeneron Science Talent Search stands as a beacon of hope and opportunity for future thinkers. T...

In a climate of constant market fluctuations and economic challenges, investors are frequently faced with the daunting task of navigating legal rights and potential recoveries when significant financial losses occur. Re...

EYLEA HD: A New Dawn in Treating Macular Edema Linked to Retinal Vein Occlusion In a significant advancement for the treatment of patients suffering from macular edema due to retinal vein occlusion (RVO), the Phase 3 cl...

Regeneron Pharmaceuticals, a renowned science-driven biotechnology company, continues to forge new grounds in therapeutic development with its recent announcements surrounding its investigational antibodies and ongoing...

In a remarkable affirmation of its commitment to sustainable business practices, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been named to the CSIMarket.com Sustainability World Index (DJSI World) for the sixth c...

The pharmaceutical landscape continues to evolve rapidly, particularly in the field of oncology, where novel therapies seek to improve outcomes for patients battling various forms of cancer. A notable development is the...

Dupixent (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU) In a significant advancement for patients suffering from Chronic Spontaneous Urticaria (CSU), the U.S. Food and...